Uncategorized The 3 Important Factors To Consider When Commercializing The CAR-T Therapy

The 3 Important Factors To Consider When Commercializing The CAR-T Therapy

Last month, Novartis’s CAR-T cell therapy CTL-019 has unanimously (10-0) won a recommended approval from FDA advisory committee to treat pediatric, young adult r/r B-cell ALL, marking one big step closer to reaching patients. The vote represents a pivotal milestone for this class of experimental treatment. The FDA is expected to make a final decision …

Read Article Read More